Healthcare - Biotechnology - NASDAQ - US
$ 9.53
-5.92 %
$ 202 M
Market Cap
-1.75
P/E
CASH FLOW STATEMENT
-103 M
OPERATING CASH FLOW
-53.6 M
INVESTING CASH FLOW
198 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Enanta Pharmaceuticals, Inc.
| Net Income | -134 M |
| Depreciation & Amortization | 2.37 M |
| Capital Expenditures | -9.06 M |
| Stock-Based Compensation | 28.2 M |
| Change in Working Capital | 8.02 M |
| Others | 2.36 M |
| Free Cash Flow | -112 M |
Cash Flow
Millions
| Sep-2023 | Sep-2022 | Sep-2021 | Sep-2020 | Sep-2019 | Sep-2018 | Sep-2017 | Sep-2016 | Sep-2015 | Sep-2014 | Sep-2013 | Sep-2012 | Sep-2011 | Sep-2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||
| Net Income | (133.8) | (121.8) | (79.0) | (36.2) | 46.4 | 72.0 | 17.7 | 21.7 | 79.0 | 34.4 | 9.6 | 21.4 | 23.3 | 7.9 |
| Depreciation & Amortization | 2.4 | 3.0 | 3.3 | 3.6 | 3.3 | 2.5 | 2.1 | 1.7 | 0.6 | 0.4 | 0.2 | 0.2 | 0.5 | 0.6 |
| Deferred Income Tax | (10.6) | 0 | 0.3 | 10.6 | (3.1) | 1.9 | (1.7) | (2.3) | 11.0 | (15.2) | 0.8 | 0 | (0.4) | 0 |
| Stock Based Compensation | 28.2 | 27.0 | 21.0 | 19.6 | 19.2 | 15.8 | 13.1 | 9.4 | 5.8 | 2.7 | 1.1 | 0.4 | 0.2 | 0.3 |
| Other Operating Activities | 2.6 | 0.2 | (2.0) | (3.5) | (5.8) | (1.2) | (0.6) | (0.7) | (3.0) | 0.2 | (1.8) | 0.5 | 2.7 | (0.5) |
| Change in Working Capital | 8.0 | 6.8 | (13.7) | 12.9 | 11.5 | (61.8) | 22.0 | 6.2 | (16.8) | (2.3) | 0.7 | 93 K | (2.4) | (18.4) |
| Cash From Operations | (103.2) | (84.8) | (70.0) | 7.1 | 71.4 | 29.2 | 52.7 | 35.8 | 76.7 | 20.2 | 10.7 | 22.6 | 24.0 | (10.2) |
| INVESTING CASH FLOW | ||||||||||||||
| Capital Expenditures | (9.1) | (2.1) | (0.8) | (1.4) | (5.4) | (3.0) | (2.5) | (4.7) | (2.3) | (1.0) | (0.6) | (0.3) | (0.4) | 37 K |
| Other Items | (44.5) | 57.0 | 37.7 | 21.3 | (81.2) | (32.4) | (2.1) | (38.9) | (85.8) | 1.5 | (68.6) | (17.8) | (17.2) | 1.7 |
| Cash From Investing Activities | (53.6) | 54.9 | 37.0 | 19.8 | (86.7) | (35.4) | (4.6) | (43.7) | (88.2) | 0.5 | (69.2) | (18.0) | (17.7) | 1.7 |
| FINANCING CASH FLOW | ||||||||||||||
| Common Stock Repurchased | 0 | (1.2) | (0.5) | (1.5) | (4.2) | (1.8) | (0.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 86 K | 79 K | 73 K | 68 K | 0 | 0 | 0 | 0 | 0 | 7 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 198.1 | 20.0 | 3.1 | 9.0 | 2.7 | 4.5 | 1.1 | 2.8 | 2.5 | 1.2 | (3.0) | (0.9) | 34 K | 15 K |
| Cash From Financing Activities | 198.1 | 20.0 | 3.1 | 9.0 | 2.6 | 4.4 | 1.0 | 2.7 | 2.5 | 1.2 | 56.9 | (0.9) | 34 K | 8 K |
| CHANGE IN CASH | ||||||||||||||
| Net Change In Cash | 41.4 | (9.9) | (29.9) | 35.9 | (12.7) | (1.8) | 49.1 | (5.1) | (9.0) | 21.8 | (1.7) | 3.7 | 6.4 | (8.5) |
| FREE CASH FLOW | ||||||||||||||
| Free Cash Flow | (112.2) | (86.9) | (70.7) | 5.6 | 66.0 | 26.2 | 50.1 | 31.1 | 74.3 | 19.2 | 10.0 | 22.4 | 23.6 | (10.2) |